When a company raises its growth outlook and the stock falls 7%, the market is telling you something specific. On Thursday, Moderna held its 2026 Analyst Day and delivered what looked, on the surface, like good news: the company expects 2026 revenue growth of 15% to 25%, compared with its original outlook of up to 10%. Shares closed at $231.35, down 6.97%.
The reason for that contradiction is straightforward. Moderna expects approximately $4 billion in cash costs in 2027, and annual cash costs of approximately $4 billion to $4.5 billion from 2027 through 2030, primarily driven by increased investment in oncology. Last November’s Analyst Day had put 2027 cash costs at $3.5 billion to $3.9 billion, on the path to cash breakeven in 2028. That target has not been abandoned in name, but the cost trajectory makes it considerably harder to reach.
The Science Is Genuinely Compelling
To be clear: the oncology bet is not speculative. Moderna highlighted that intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 42% versus Keytruda alone in the Phase 3 INTerpath-001 trial in completely resected stage IIB-IV melanoma. That is a meaningful clinical result, and it justifies serious capital commitment. The question investors are wrestling with is not whether the science works. It is whether the price already reflects success.
Intismeran, given with Merck’s Keytruda, cut the risk of melanoma recurrence or death by 42% in Phase 3, so spending to launch it makes sense. But Moderna’s valuation is no longer a simple shorthand like “44x sales.” Depending on the dataset and the exact time window you look at, it can be materially lower than that. That valuation gap is precisely the problem. Good clinical data was expected. What was not fully priced in was four consecutive years of elevated spending that pushes profitability further out.
Investing for the Future, or Spending Money You Don’t Have?
This is the central question every long-term investor should ask when a growth company commits to heavy multi-year spending. The honest answer, with Moderna, is that it sits somewhere in between, and knowing which side of that line it is closer to requires watching a few specific things.
First, revenue growth needs to stay ahead of the cost curve. Moderna reported third-quarter revenue of $1.3 billion and 29% revenue growth in that quarter, alongside the U.S. approval of mFLUSIVA, its fifth approved product globally. That momentum is real. If the infectious disease vaccine franchise keeps expanding, the cash costs of oncology become more manageable.
Second, the MSCI inclusion adds a structural tailwind that is easy to underestimate. Moderna is one of only two additions to the MSCI World Index in the November 2026 review, alongside Canada’s Aritzia, with all changes taking effect after the close of trading on November 30, 2026. Index inclusion forces passive funds to buy the stock regardless of their view on oncology spending, which creates a demand floor that did not exist last week.
What to Watch
Valuation concerns have been a persistent overhang, with widely followed consensus price targets sitting below the current trading price. Several Wall Street firms also remain cautious. Citi, for instance, has maintained a Sell rating with a price target well below recent levels.
For investors already holding Moderna, Thursday’s selloff is a reminder that great science and expensive stock prices coexist uncomfortably. For those watching from the sidelines, the more interesting moment may come after November 30, when index-driven buying settles and the stock has to stand on its cash flow story alone. That is the test worth waiting for.
The broader lesson here is durable: when evaluating any company committing to years of heavy spending, demand a clear line between investment that creates compounding value and spending that simply delays the reckoning. With Moderna’s melanoma data, that line exists. Whether the market gives it time to prove out is a different question entirely.
